314 related articles for article (PubMed ID: 20838435)
1. The proneural molecular signature is enriched in oligodendrogliomas and predicts improved survival among diffuse gliomas.
Cooper LA; Gutman DA; Long Q; Johnson BA; Cholleti SR; Kurc T; Saltz JH; Brat DJ; Moreno CS
PLoS One; 2010 Sep; 5(9):e12548. PubMed ID: 20838435
[TBL] [Abstract][Full Text] [Related]
2. Phospholipase C Beta 1: a Candidate Signature Gene for Proneural Subtype High-Grade Glioma.
Lu G; Chang JT; Liu Z; Chen Y; Li M; Zhu JJ
Mol Neurobiol; 2016 Nov; 53(9):6511-6525. PubMed ID: 26614510
[TBL] [Abstract][Full Text] [Related]
3. Co-expression of mitosis-regulating genes contributes to malignant progression and prognosis in oligodendrogliomas.
Liu Y; Hu H; Zhang C; Wang H; Zhang W; Wang Z; Li M; Zhang W; Zhou D; Jiang T
Oncotarget; 2015 Nov; 6(35):38257-69. PubMed ID: 26468983
[TBL] [Abstract][Full Text] [Related]
4. Transforming growth factor beta induced (TGFBI) is a potential signature gene for mesenchymal subtype high-grade glioma.
Pan YB; Zhang CH; Wang SQ; Ai PH; Chen K; Zhu L; Sun ZL; Feng DF
J Neurooncol; 2018 Apr; 137(2):395-407. PubMed ID: 29294230
[TBL] [Abstract][Full Text] [Related]
5. Somatostatin receptor 2A in gliomas: Association with oligodendrogliomas and favourable outcome.
Kiviniemi A; Gardberg M; Kivinen K; Posti JP; Vuorinen V; Sipilä J; Rahi M; Sankinen M; Minn H
Oncotarget; 2017 Jul; 8(30):49123-49132. PubMed ID: 28467778
[TBL] [Abstract][Full Text] [Related]
6. DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas.
Paul Y; Mondal B; Patil V; Somasundaram K
Clin Epigenetics; 2017; 9():32. PubMed ID: 28392842
[TBL] [Abstract][Full Text] [Related]
7. Identification of a five B cell-associated gene prognostic and predictive signature for advanced glioma patients harboring immunosuppressive subtype preference.
Zhang C; Li J; Wang H; Song SW
Oncotarget; 2016 Nov; 7(45):73971-73983. PubMed ID: 27738332
[TBL] [Abstract][Full Text] [Related]
8. Molecular subtypes of glioblastoma are relevant to lower grade glioma.
Guan X; Vengoechea J; Zheng S; Sloan AE; Chen Y; Brat DJ; O'Neill BP; de Groot J; Yust-Katz S; Yung WK; Cohen ML; Aldape KD; Rosenfeld S; Verhaak RG; Barnholtz-Sloan JS
PLoS One; 2014; 9(3):e91216. PubMed ID: 24614622
[TBL] [Abstract][Full Text] [Related]
9. A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients.
Zhu Z; Lan Y; Wang L; Ge J; Wang J; Liu F; He Z; Zhang H; Luo M; Lin D; Tan Y; Xu Y; Luo T
BMC Cancer; 2020 Nov; 20(1):1072. PubMed ID: 33167941
[TBL] [Abstract][Full Text] [Related]
10. SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II-III Diffuse Gliomas.
Zhang YA; Zhou Y; Luo X; Song K; Ma X; Sathe A; Girard L; Xiao G; Gazdar AF
EBioMedicine; 2016 Nov; 13():80-89. PubMed ID: 27840009
[TBL] [Abstract][Full Text] [Related]
11. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.
Barbashina V; Salazar P; Holland EC; Rosenblum MK; Ladanyi M
Clin Cancer Res; 2005 Feb; 11(3):1119-28. PubMed ID: 15709179
[TBL] [Abstract][Full Text] [Related]
12. Oncostatin-M differentially regulates mesenchymal and proneural signature genes in gliomas via STAT3 signaling.
Natesh K; Bhosale D; Desai A; Chandrika G; Pujari R; Jagtap J; Chugh A; Ranade D; Shastry P
Neoplasia; 2015 Feb; 17(2):225-37. PubMed ID: 25748242
[TBL] [Abstract][Full Text] [Related]
13. PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients.
Draaisma K; Wijnenga MM; Weenink B; Gao Y; Smid M; Robe P; van den Bent MJ; French PJ
Acta Neuropathol Commun; 2015 Dec; 3():88. PubMed ID: 26699864
[TBL] [Abstract][Full Text] [Related]
14. A glycolysis-based ten-gene signature correlates with the clinical outcome, molecular subtype and IDH1 mutation in glioblastoma.
Chen C; Shi Y; Li Y; He ZC; Zhou K; Zhang XN; Yang KD; Wu JR; Kung HF; Ping YF; Bian XW
J Genet Genomics; 2017 Nov; 44(11):519-530. PubMed ID: 29169920
[TBL] [Abstract][Full Text] [Related]
15. Gene expression analyses of grade II gliomas and identification of rPTPbeta/zeta as a candidate oligodendroglioma marker.
Hägerstrand D; Smits A; Eriksson A; Sigurdardottir S; Olofsson T; Hartman M; Nistér M; Kalimo H; Ostman A
Neuro Oncol; 2008 Feb; 10(1):2-9. PubMed ID: 18003890
[TBL] [Abstract][Full Text] [Related]
16. Identification of Periostin as a Potential Biomarker in Gliomas by Database Mining.
Faried A; Hermanto Y; Tjahjono FP; Valentino A; Arifin MZ
World Neurosurg; 2020 Mar; 135():e137-e163. PubMed ID: 31785437
[TBL] [Abstract][Full Text] [Related]
17. An Immune-Related Signature for Predicting the Prognosis of Lower-Grade Gliomas.
Zhang H; Li X; Li Y; Chen B; Zong Z; Shen L
Front Immunol; 2020; 11():603341. PubMed ID: 33363544
[TBL] [Abstract][Full Text] [Related]
18. Coexpression network analysis identifies transcriptional modules related to proastrocytic differentiation and sprouty signaling in glioma.
Ivliev AE; 't Hoen PA; Sergeeva MG
Cancer Res; 2010 Dec; 70(24):10060-70. PubMed ID: 21159630
[TBL] [Abstract][Full Text] [Related]
19. Integrated Transcriptomic Analysis of Necrosis-related Gene in Diffuse Gliomas.
Wang J; Ma J
J Neurol Surg A Cent Eur Neurosurg; 2019 Jul; 80(4):240-249. PubMed ID: 30934097
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of alpha4 chain-containing laminins in human glial tumors identified by gene microarray analysis.
Ljubimova JY; Lakhter AJ; Loksh A; Yong WH; Riedinger MS; Miner JH; Sorokin LM; Ljubimov AV; Black KL
Cancer Res; 2001 Jul; 61(14):5601-10. PubMed ID: 11454714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]